Denali Therapeutics Inc. DNLI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 70.13M | -127.55M | -128.45M | -128.55M | -126.90M |
| Total Depreciation and Amortization | 4.49M | 4.48M | 3.76M | 3.78M | 3.86M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -168.65M | 25.69M | 20.98M | 21.21M | 21.97M |
| Change in Net Operating Assets | -23.41M | 382.00K | -27.50M | 5.02M | -6.22M |
| Cash from Operations | -117.44M | -97.00M | -131.20M | -98.54M | -107.30M |
| Capital Expenditure | -1.01M | -805.00K | -2.47M | -1.52M | 1.38M |
| Sale of Property, Plant, and Equipment | 194.00M | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -176.80M | -103.27M | 96.93M | 22.29M | 56.45M |
| Cash from Investing | 16.19M | -104.08M | 94.46M | 20.77M | 57.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -22.00K | -21.00K | -17.00K | -16.00K | -1.36M |
| Issuance of Common Stock | 2.66M | 15.01M | 19.06M | 920.47M | 583.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -45.00K | 0.00 | 200.00M | -728.32M | -- |
| Cash from Financing | 2.59M | 14.98M | 219.04M | 192.13M | -778.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.66M | -186.10M | 182.30M | 114.36M | -50.24M |